Swiss National Bank Jounce Therapeutics, Inc. Transaction History

Swiss National Bank

  • $150 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 13, 2019
SELL
$2.69 - $6.71 $66,443 - $165,737
-24,700 Closed
0 $0
Q4 2017

Feb 07, 2018
BUY
$12.52 - $17.82 $141,476 - $201,366
11,300 Added 84.33%
24,700 $315,000
Q3 2017

Nov 03, 2017
BUY
$11.17 - $16.99 $149,678 - $227,665
13,400
13,400 $209,000

Others Institutions Holding JNCE

# of Institutions
4
Shares Held
720K
Call Options Held
0
Put Options Held
0
View Full List

About Jounce Therapeutics, Inc.

JNCE Quotes by TradingView
  • Ticker JNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,694,200
  • Description
  • Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...
More about JNCE
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email